Tumor characteristics of hepatocellular carcinoma after direct-acting antiviral treatment for hepatitis C: Comparative analysis with antiviral therapy-naive patients

Table 3 Comparison of laboratory data in both groups

	Group I	Group II	P value
	HCC with previous DAAs (n = 151)	HCC without previous DAAS (n = 346)
HB (mean ± SD)	10.41 ± 1.88	10.78 ± 1.99	0.02a
TLC (mean ± SD)	6.55 ± 6.20	7.74 ± 8.60	0.004b
PLATELETS (mean ± SD)	147.28 ± 79.76	135.95 ± 61.17	0.22
TBIL (median)	3.07	2.5	0.93
DBIL (median)	0.7	0.9	0.84
ALB (mean ± SD)	3.32 ± 1.47	2.98 ± 0.85	0.004b
INR	1.31 ± 0.35	1.44 ± 0.47	0.4
ALT (median)	77	54	0.001c
AST (median)	76	70	0.62
CREAT (mean ± SD)	1.21 ± 0.45	1.43 ± 3.67	0.15
UREA (mean ± SD)	40.81 ± 16.01	54.93 ± 46.17	0.04a
AFP (median)	184.0	60.0	< 0.001c

^aP < 0.05.

^bP < 0.01.

^cP < 0.001.

HCC: Hepatocellular carcinoma; CBC: Complete blood picture; TLC: Total leucocytic count; TBIL: Total bilirubin; DBIL: Direct bilirubin; ALB: Albumin, ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; AFP: Alfa feto protein.